HORC-020

N/A

Report date: 2025/01/26 16:01:33

Base Information

Drug NameHORC-020

Drug Alias Nameanti-CEA CAR T-cell therapy (HumOrigin/University of Cologne)HORC-020

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 modulators

TargetsCarcinoembryonic antigen related cell adhesion molecule 5

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesHumOrigin Inc

China Registration ClassN/A

Develop Information

Active CompaniesHumOrigin Inc University Of Cologne

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A